Dosage of Primogyn C in details
Primogyn C Dosage
Applies to the following strengths: 0.05 mg; 0.5 mg; 0.02 mg
Usual Adult Dose for:
- Postmenopausal Symptoms
- Prostate Cancer
- Primary Ovarian Failure
- Menstrual Disorders
Additional dosage information:
- Renal Dose Adjustments
- Liver Dose Adjustments
- Dialysis
- Other Comments
Usual Adult Dose for Postmenopausal Symptoms
10 to 50 mcg orally once a day
Comment:
-Given on a cyclical basis, 3 weeks on and 1 week off.
-Addition of progestogen is not recommended in women without a uterus who did not have endometriosis.
-A progestogen should be added for at least 12 to 14 days every month (28-day cycle) in women with a uterus (or in endometriosis when endometrial foci are present despite hysterectomy).
-Start therapy any time in women with amenorrhea.
-Start therapy on the first day of bleeding in women who are menstruating.
Use: For postmenopausal symptoms due to estrogen deficiency (including prevention of postmenopausal osteoporosis)
Usual Adult Dose for Prostate Cancer
0.15 to 1.5 mg orally once a day
Use: Palliative treatment of prostatic cancer
Usual Adult Dose for Primary Ovarian Failure
10 to 50 mcg orally once a day
Comments:
-Usually given on a cyclical basis.
-Follow initial estrogen by combined estrogen/progestogen.
Use: Hormone replacement therapy (HRT) for failure of ovarian development (e.g., in patients with gonadal dysgenesis where initial estrogen therapy is later followed by combined estrogen/progestogen therapy)
Usual Adult Dose for Menstrual Disorders
20 to 50 mcg orally once a day from day 5 to day 25 of each cycle
Comments:
-A progestogen is given daily throughout the cycle or from days 15 to 25 of the cycle.
-Take a missed dose as soon as it is remembered; if it is nearly time for the next dose then the patient should wait until then. Two doses should not be taken together. Forgetting a dose may increase the likelihood of break-through bleeding and spotting.
Use: For disorders of menstruation (given in conjunction with a progestogen)
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
This drug is contraindicated in acute liver disease or a history of liver disease as long as liver function tests have failed to return to normal.
Dialysis
Data not available
Other Comments
Administration advice:
-A missed dose should be taken as soon as remembered. The missed dose should be skipped if it is almost time for the next scheduled dose.
Patient advice:
-Forgetting a dose may increase the chances of breakthrough bleeding
-See your doctor for regular check ups
-Check your breasts regularly for any changes
-Go for regular breast screening and cervical smear tests
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medical Disclaimer
More about Primogyn C
- Primogyn C Side Effects
- During Pregnancy or Breastfeeding
- Drug Interactions
- Support Group
- Drug class: estrogens
Related treatment guides
- Breast Cancer, Palliative
- Hypoestrogenism
- Oophorectomy
- Postmenopausal Symptoms
- Primary Ovarian Failure
- Prostate Cancer
Primogyn C interactions
DRUG/LABORATORY TEST INTERACTIONS
1. Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.
2. Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioimmunoassay. T3 resin uptake is decreased, reflecting the elevated TBG. Free T4 and free T3 concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone.
3. Other binding proteins may be elevated in serum, (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating corticosteroids and sex steroids, respectively. Free hormone concentrations may be decreased. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).
4. Increased plasma HDL and HDL2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglyceride levels.
5. Impaired glucose tolerance.
6. Reduced response to metyrapone test.
References
- DailyMed. "ETHINYL ESTRADIOL; NORETHINDRONE ACETATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- FDA/SPL Indexing Data. "423D2T571U: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Estrogens". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Primogyn C are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Primogyn C. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yetConsumer reported doses
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
